What smart money is saying about Insmed Incorporated
4 funds in our archive have pitched Insmed Incorporated, most recently Baron Health Care Fund in June 2026.
Insmed Incorporated operates as a biopharmaceutical enterprise focused on creating and introducing medical solutions for individuals facing severe and uncommon health conditions. The company's marketed treatment, ARIKAYCE, is administered to adult patients suffering from Mycobacterium avium complex (MAC) lung disease, serving as a component of a broader antibacterial drug regimen. In its development pipeline, Insmed is advancing Brensocatib, an oral and reversible inhibitor targeting dipeptidyl peptidase 1, which is being investigated for its potential in treating bronchiectasis and other disorders mediated by neutrophils. Additionally, the firm is developing Treprostinil Palmitil Inhalation Powder, an inhaled version of the treprostinil palmitil prodrug, designed to address pulmonary arterial hypertension and various other rare lung ailments. Founded in 1988, Insmed Incorporated maintains its primary corporate offices in Bridgewater, New Jersey.
Get an email when a fund buys, sells or pitches it
Fund signal · last 12 months
9 lettersToo few moves on Insmed Incorporated yet for a clear signal
Moves described in fund letters in our archive. A sentence published word for word by several funds of one house in the same quarter counts once.
Position history
Between Q4 2024 and Q3 2026, 17 fund letters reported a position in Insmed Incorporated, with 2 buys (opened or added) and 4 sells (trimmed or exited).
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 0 | 0 |
| Q2 2026 | 5 | 0 | 2 | 1 |
| Q1 2026 | 1 | 1 | 0 | 1 |
| Q4 2025 | 1 | 0 | 0 | 0 |
| Q3 2025 | 5 | 1 | 2 | 1 |
| Q2 2025 | 1 | 0 | 0 | 0 |
| Q1 2025 | 2 | 0 | 0 | 0 |
| Q4 2024 | 0 | 0 | 0 | 1 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 17 positions · 7 moves
- September 2026
Listed in Artisan Partners U.S. Mid-Cap Growth Strategy’s reported holdings.
Insmed Incorporated - HoldsRhenman Healthcare Equity L/SAugust 2026
“The best contributors for the month were all biopharma names, including Iovance, Insmed and Merck.”
Insmed Incorporated - June 2026
“Our biggest detractors in Q2 were Insmed, ROBLOX and Insulet.”
Insmed Incorporated - June 2026
“We trimmed the position during the quarter.”
Insmed Incorporated - June 2026
“Top detractors from performance for the quarter Contribution to Return (%) Insmed Incorporated (0.97) Intuitive Surgical, Inc. (0.50) Gilead Sciences, Inc. (0.34) AstraZeneca PLC (0.25) IDEXX Laboratories, Inc. (0.13) Insmed Incorporated is a biotechnology company with three lead pulmonology assets that we believe can collectively generate more than $8 billion in peak sales.”
Insmed Incorporated - June 2026
“Insmed is a commercial-stage biotechnology company focused on pulmonary diseases. BRINSUPRI® continued its rapid launch, with robust patient uptake and encouraging third-party data. While Q1 sales came in modestly below elevated investor expectations, reflecting concerns around discontinuation rates, continuation on therapy and typical early-year seasonality, the underlying launch trajectory remains encouraging. We continue to view BRINSUPRI® as a significant long-term opportunity. Our due diligence suggests the therapy remains well tolerated and is on track to achieve blockbuster-level sales. We trimmed the position during the quarter.”
Insmed Incorporated - June 2026
“Insmed shares fell after sales of the biopharmaceutical company’s new lung drug Brinsupri fell short of analysts’ expectations. We exited the position during the quarter.”
Insmed Incorporated - March 2026
“Insmed Inc., a developer of therapies for patients with serious and rare diseases, dropped -6%. The launch of Brinsupri is well ahead of expectations. That medication received FDA approval last summer as the first treatment for non-cystic fibrosis bronchiectasis, a chronic lung disease. Management also noted that Arikayce sales were below the Street. That prescription antibiotic is used to treat refractory Mycobacterium avium complex lung disease. In our view, Brunsupri is their primary driver, with expectations of $1 billion in sales for 2026. We added to the position.”
Insmed Incorporated - December 2025
“While health care represented our weakest sector in the quarter, it also produced two of our top individual performers – medical device maker Penumbra and biotech Insmed, both of which continue to see strong commercial execution and growth.”
Insmed Incorporated - September 2025
“Among our top contributors were Argenx, Insmed and Lattice Semiconductor.”
Insmed Incorporated - New positionRiverPark Next Century Large Growth FundSeptember 2025
“3Q Portfolio Activity • In technology, we are inline and we maintain significant exposure to the sector as growth fundamentals remain strong in many of the large index positions as well as in many other areas. • In consumer, we are underweight and continue to focus on companies we believe have long-term secular growth opportunities in online and offline retail, online streaming content, EVs, among others. • Overweight in industrials driven by companies with what we believe have secular growth drivers in areas such as aerospace, power generation and AI infrastructure buildout, among others. • The portfolio is overweight the financial sector. • The portfolio is underweight the health care sector. • We added 5 new positions in Q3: o two in technology: MongoDB, Oracle Corp o one each in health care (Insmed), industrials (GE Vernova), financials (Robinhood Markets)”
Insmed Incorporated - September 2025
“Insmed is a commercial-stage biotech company focused on serious pulmonary diseases. Its lead product is ARIKAYCE®, an inhaled antibiotic that treats lung infections unresponsive to standard therapies. The company recently received FDA approval for Brinsupri™, the first once-daily oral treatment for non-cystic fibrosis bronchiectasis—a chronic and progressive lung condition with limited treatment options. With over one million diagnosed patients across the US, Europe and Japan, Brinsupri™ addresses a major unmet need, and we expect rapid adoption. In our view, Insmed also has a promising pipeline, including a third de-risked drug candidate with multibillion-dollar potential. Given the company’s increasing market capitalization, we began to pare back our CropSM position.”
Insmed Incorporated - September 2025
“Insmed (INSM) released positive pipeline data, and the stock reached our price target.”
Insmed Incorporated - September 2025
“Insmed Inc., a biopharmaceutical company focused on developing and commercializing therapies for patients with rare diseases, rallied 43%.”
Insmed Incorporated - June 2025
Listed in Loomis Sayles Small Mid Cap Growth Fund’s reported holdings.
Insmed Incorporated - March 2025
“Insmed Inc., a biopharmaceutical company engaged in developing therapies for patients with rare diseases, rose 10%.”
Insmed Incorporated - March 2025
“Within the healthcare sector, notable performers included Halozyme Therapeutics, Inc., Axsome Therapeutics, Inc., and Insmed Inc. Halozyme licenses its Enhanze auto-injector technology, which enables the conversion of intravenous (IV) formulated biologic and small molecule drugs to be delivered via subcutaneous injection. The technology improves patient convenience and tolerability, and for drug developers extends market exclusivity beyond expiration of patent protection on the partner’s original proprietary IV drug. During the quarter, Halozyme reported 4Q 2024 financial results above consensus expectations with royalties and adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) exceeding the prior guidance ranges. Most importantly, the company reiterated its guidance for 2025 and its longer-term outlook (2026-28). Axsome, which is a commercial-stage biotechnology company developing treatments for central nervous system (CNS) conditions, entered into a settlement agreement with Teva Therapeutics that resolved all patent litigation related to Axsome’s AUVELITY product used to treat major depressive disorder (MDD). As a result, AUVELITY is protected from generic versions until 2038 or even 2039 if pediatric exclusivity is granted. Additionally, AUVELITY saw 10% new prescription growth during the quarter, outpacing the anti-depressant market, which grew at 1%. Insmed focuses on developing innovative therapeutics for rare pulmonary diseases, and its promising pipeline contributed positively to the Fund’s performance. During the quarter, the Food and Drug and Administration (FDA) granted priority review for the company’s New Drug Application for brensocatib for patients with non-cystic fibrosis bronchiectasis.”
Insmed Incorporated
Also mentioned · 2
These funds discuss Insmed Incorporated as a competitor, benchmark or comparable, without disclosing a position in it.
- June 2026
“The largest contributors to relative returns were CrowdStrike, Vertiv, Snowflake, Broadcom and not owning Insmed.”
Insmed Incorporated - MentionedTimesSquare U.S. Mid Cap GrowthJune 2026
“Insmed Inc. develops and commercializes therapies for patients with serious and rare diseases.”
Insmed Incorporated
Fund coverage · 4 theses
- Baron Health Care FundJune 2026
Insmed has a pulmonology pipeline with multi-billion-dollar peak sales potential, led by Brinsupri and once-daily TPIP.
Read the full thesis - Artisan Global Discovery StrategyMarch 2026
Insmed is a pulmonary-focused biotech with durable ARIKAYCE revenue and a promising Brinsupri launch that could drive a meaningful profit cycle.
Read the full thesis - Orbis Global EquitySeptember 2025
Insmed is poised for sustained profitability following the FDA approval of its bronchiectasis treatment, brensocatib, while also advancing its promising pipeline in respiratory diseases.
Read the full thesis - Baron Health Care FundDecember 2024
Insmed Incorporated is expected to generate over $8 billion in peak sales from its lead drugs, including Brensocatib, which shows promise for treating non-cystic fibrosis bronchiectasis.
Read the full thesis
Read every full thesis on Insmed Incorporated
Read all 4 theses in full, with each fund's reasoning, and get unlimited access to the archive.
View plans→